Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for… EP News Bureau Apr 10, 2025 AXS-05 emerges as a potential first-in-class, non-antipsychotic treatment for Alzheimer’s agitation, positioning Axsome…
FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment EP News Bureau Jan 15, 2025 LEQEMBI’s subcutaneous formulation could simplify maintenance therapy for Alzheimer’s patients, offering a 15-second at-home…
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab… EP News Bureau Oct 25, 2024 Australia’s Alzheimer’s patients await potential treatment shift as TGA reviews Lilly’s donanemab following lecanemab rejection
